Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform  with approved active pharmaceutical ingredients (APIs). Our extensive experience with liposome science allows us to combine speed of onset and duration of benefit and to improve API concentrations at target tissues while decreasing unwanted systemic exposures.

Our BioSeizer™ lipid formulation technology enables local sustained release of APIs at the site of disease or injury, which is applied to our TLC599, TLC399 and TLC590 programs. Our NanoX™ targeted delivery technology enables prolonged pharmacokinetic (PK) profiles and enhanced distribution of liposome-encapsulated APIs at the desired site, which is applied to our TLC178 program.

Our technologies can be used with a broad range of APIs with a simplified and scalable manufacturing process. Because our product candidates use already approved APIs, we can utilize the simplified 505(b)(2) regulatory pathway for approval in the United States. We have used our proprietary technology platforms to assemble a diverse portfolio of product candidates that target significant areas of unmet medical need in pain management, ophthalmology, and oncology.
 
TLC looks for two types of industry partners worldwide: licensing partners that have the most appropriate distribution network for a particular asset (i.e. presence in the geography and experience with the appropriate indication) as well as co-development partners for collaborations to build new products using its technology.
  • Keelung Hong / PhD, Chairman and CEO

    Keelung Hong / PhD, Chairman and CEO

    Over 40 years history as a lipid formulation pioneer.
    100 peer-reviewed publications.
  • George Yeh / President

    George Yeh / President

    Over 20 years experience in financing. Led financing rounds of increasing size over the past 14 years at the company.
We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform  with approved active pharmaceutical ingredients (APIs). Our extensive experience with liposome science allows us to combine speed of onset and duration of benefit and to improve API concentrations at target tissues while decreasing unwanted systemic exposures.

Our BioSeizer™ lipid formulation technology enables local sustained release of APIs at the site of disease or injury, which is applied to our TLC599, TLC399 and TLC590 programs. Our NanoX™ targeted delivery technology enables prolonged pharmacokinetic (PK) profiles and enhanced distribution of liposome-encapsulated APIs at the desired site, which is applied to our TLC178 program.

Our technologies can be used with a broad range of APIs with a simplified and scalable manufacturing process. Because our product candidates use already approved APIs, we can utilize the simplified 505(b)(2) regulatory pathway for approval in the United States. We have used our proprietary technology platforms to assemble a diverse portfolio of product candidates that target significant areas of unmet medical need in pain management, ophthalmology, and oncology.
 
TLC looks for two types of industry partners worldwide: licensing partners that have the most appropriate distribution network for a particular asset (i.e. presence in the geography and experience with the appropriate indication) as well as co-development partners for collaborations to build new products using its technology.
Pipeline & Platform